Zhao F, Darling JE, Gibbs RA, Hougland JL
Bioorg Med Chem Lett. 2015 May 15. pii: S0960-894X(15)00459-X. doi: 10.1016/j.bmcl.2015.05.009. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/26009163
Inhibitors of ghrelin O-acyltransferase (GOAT) have untapped potential as therapeutics targeting obesity and diabetes. We report the first examples of GOAT inhibitors incorporating a triazole linkage as a biostable isosteric replacement for the ester bond in ghrelin and amide bonds in previously reported GOAT inhibitors. These triazole-containing inhibitors exhibit sub-micromolar inhibition of the human isoform of GOAT (hGOAT), and provide a foundation for rapid future chemical diversification and optimization of hGOAT inhibitors.
Copyright © 2015 Elsevier Ltd. All rights reserved.
The Foundation for Prader-Willi Research (federal tax id 31-1763110) is a nonprofit corporation with federal tax exempt status as a public charity under section 501(c)(3).
The mission of FPWR is to eliminate the challenges of Prader-Willi syndrome through the advancement of research and therapeutic development.
Foundation for Prader-Willi Research
Phone: 888-322-5487
Email: info@fpwr.org
FPWR
440 N Barranca Ave #3620
Covina, CA 91723
Copyright © 2020. All Rights Reserved. Terms of Use. Privacy Policy. Copyright Infringement Policy. Disclosure Statement.
